Index Ventures raises EUR350m for new early stage technology fund
The new fund of Index Ventures will invest in seed and early-stage teams wherever they are to help finance innovations across some of the major areas in which Index is actively investing, including: big data, cloud (consumer & enterprise), commerce (especially fashion), financial services, games, mobile and marketplaces.
Index aims to be the partner of choice for outstanding European & Israeli born companies looking to build global category leaders. The team stresses the opportunities for European start-ups in the official Blog of Index Ventures: “While technology adoption is increasingly rapid and worldwide, we continue to believe that Europe will be fertile ground to discover and help develop world beating innovations. In fact, even while Europe is facing massive macroeconomic challenges, at the same time we have seen very clearly that European start-ups are coming of age. In fact in our portfolio alone there are now at least 20 European born private companies with significant scale – in 2011 these companies alone had combined 2011 revenues of €1.3bn and y/y growth of around 75% – plus these are businesses which have created more than 5,000 new jobs in the last 10 years.”
The Index portfolio includes several companies from Switzerland, e.g. GlycoVaxyn, Housetrip, Molecular Partners or Fontself.
Are Swiss entrepreneurs too risk-averse?
In an interview with Swissinfo Stéphane Garelli, head of the IMD World Competitiveness Center in Lausanne, says that Swiss founders don’t “dream big”. What do you think? Send us a mail: news@startupticker.ch
The Editorial Team

















